軽度から中等度の高血圧に対するジレベシランによるRNA干渉:KARDIA-1ランダム化臨床試験
George L Bakris1, Manish Saxena2,3, Anil Gupta4
1University of Chicago Medicine, Chicago, Illinois.
JAMA
|February 16, 2024
まとめ
ジレベシランはRNA干渉療法で,血管新生素を標的として,高血圧の成人の血圧を有意に低下させた. 3 か 6 か月ごとに投与すると有効性が示され,管理可能な安全性プロファイルが示されました.
科学分野:
- 心血管医学
- 薬理学について
- 遺伝学
背景:
- レニン・アンジオテンシン・アルドステロン系は,血管新生素を主要前駆体として,血圧 (BP) を調節する.
- ジレベシランは,肝臓の血管新生素合成を抑制するために設計された研究中のRNA干渉療法薬です.
研究 の 目的:
- 軽度から中等度の高血圧の成人における様々なジレベシラン用薬の抗高血圧効果と安全性を評価する.
主な方法:
- 高血圧の394人の成人を対象とした2段階のランダム化,ダブルブラインド,投与範囲の試験です.
- 参加者は,皮下ジレベシラン (150,300,または600 mg 6ヶ月ごとに,または300 mg 3ヶ月ごとに) またはプラセボを6ヶ月間投与された.
- 主なエンドポイントは,24時間の平均出動性シストリック血圧 (SBP) の変化でした.
主要な成果:
- ジレベシランは,すべての試験用量および間隔で3ヶ月でプラセボと比較してSBPを有意に低下させた (例えば,3か6ヶ月ごとに300mgで-16. 7mmHg).
- 副作用はプラセボ (50. 7%) よりもジレベシラン (60. 9%) により頻繁であったが,深刻な副作用はプラセボ (6. 7%) よりもジレベシラン (3. 6%) により少ない.
- 注射部位の反応と軽度の高カリミアを含む非重症薬剤関連有害事象.
結論:
- ジレベシランは,軽度から中等度の高血圧を有する成人に有意な抗高血圧効果を示した.
- 治療薬は,一般的には好ましい安全性プロファイルで,頻度が低い (3 か 6 か月ごとに) 投与の可能性を示した.
関連する概念動画
01:25Antihypertensive Drugs: Direct Renin Inhibitors
629
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
629
01:15Antihypertensive Drugs: Thiazide-Class Diuretics
635
Thiazide diuretics are sulfonamide derivatives featuring a benzothiadiazine ring system in their molecular structure. Based on this structure, thiazide diuretics can be categorized into two groups: thiazide-type and thiazide-like diuretics. Thiazide-type diuretics, including hydrochlorothiazide and chlorothiazide, consist of a benzothiadiazine backbone with an attached sulfonamide group. Thiazide-like diuretics, such as chlorthalidone and indapamide, lack the thiazide ring but demonstrate...
635
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
638
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
638
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
731
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
731
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
431
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
431
01:28Antihypertensive Drugs: Potassium-Sparing Diuretics
554
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
554